Living better with mesothelioma. When you choose the right team of experts, it can be done.
That’s where the doctors at the Mesothelioma and Thoracic Oncology Treatment and Research Center can make a difference. Part of the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, our internationally recognized team specializes in the diagnosis, treatment and cutting-edge research of mesothelioma and other asbestos-related diseases.
The center is one of few in the world to house several mesothelioma experts, including those who treat pleural (in the chest) and peritoneal (in the abdomen) mesothelioma. Together, these experts use a finely tuned multidisciplinary (multi-D) approach to find the best treatment solutions for patients with this difficult disease.
The center is led by Dr. Joseph Friedberg, an international expert in thoracic oncology. He is joined by mesothelioma experts in surgical, medical and radiation oncology; pulmonary and integrative medicine; pathology; radiology; and palliative care. This comprehensive team works together with each patient to create a treatment plan that preserves life and quality-of-life for as long as possible.
Our patients are truly at the center of their care. A dedicated mesothelioma nurse coordinates appointments and treatment with medical, surgical and radiation oncologists. She even handles authorization with your health insurance company. This “one-stop shopping” approach lowers patient stress and inconvenience and improves communication. It results in the ideal way to tackle the complex care required for mesothelioma.
Dr. Joseph Friedberg explains why pleural mesothelioma is different from other cancers.
Mesothelioma Quick Facts...
In the United States, 2,000 to 3,000 patients are diagnosed with malignant pleural mesothelioma each year. Malignant peritoneal mesothelioma is even rarer, with about 350 to 500 cases diagnosed annually in the U.S.
Pleural mesothelioma affects men more frequently than women, and is more common in white Americans. Peritoneal mesothelioma affects women nearly as often as men.
The median age of onset of pleural mesothelioma symptoms is 70. Peritoneal mesothelioma patients are usually younger, with a median age of 53.
The latent period between exposure to asbestos and the onset of mesothelioma symptoms can be 20 to 40 years.
For malignant pleural mesothelioma, the median survival time is between 4 and 12 months, depending on the stage of presentation. The three-year survival is 10 percent, and the overall five-year survival is approximately 5 percent.
For malignant peritoneal mesothelioma, the median survival time is between 6 and 12 months. The relative five-year survival is 16 percent.